Robert Zalewski-Zaragoza, MD

Geoffrey Grammer, MD closes this series highlighting the administration options of esketamine, its safety profile, and the importance of monitoring patients using this treatment.

Robert Zalewski-Zaragoza, MD expands on the option of esketamine for treatment resistant depression, highlighting the unique mechanism of action and application.

William Sauve, MD shares the growing landscape of treatments for treatment resistant depression (TRD) and their mechanism of action, such as brain stimulation through electroconvulsive therapy or medication such as esketamine.

Harman Deol, MD begins this series presenting an overview of treatment resistant depression (TRD), highlighting its prevalence along with its impact on patients and the healthcare system.